Baseline characteristics
| . | Total (N = 88) . | Patient cohort, n (%) . | P . | ||
|---|---|---|---|---|---|
| DFCI off-trial (n = 47 [53%]) . | DFCI trial (n = 23 [26%]) . | WUSTL trial (n = 18 [20%]) . | |||
| Age, y | |||||
| Median (range) | 58 (30-72) | 58 (30-72) | 57 (42-69) | 60 (38-65) | .97* |
| >60 | 36 (41) | 20 (43) | 8 (35) | 8 (44) | .84† |
| Male sex | 64 (73) | 32 (68) | 15 (65) | 17 (94) | .056† |
| Stage at diagnosis | |||||
| 1 | 1 (1) | 0 (0) | 0 (0) | 1 (6) | .80‡ |
| 2 | 1 (1) | 1 (2) | 0 (0) | 0 (0) | |
| 3 | 11 (12) | 7 (15) | 3 (13) | 1 (6) | |
| 4 | 75 (85) | 39 (83) | 20 (87) | 16 (89) | |
| ECOG PS | |||||
| 0-1 | 84 (95) | 47 (100) | 22 (96) | 15 (83) | .013† |
| 2 | 4 (5) | 0 (0) | 1 (4) | 3 (17) | |
| Days from diagnosis to treatment, median (range) | 32 (0-1539) | 31 (3-1388) | 40 (12-245) | 21 (0-1539) | .031* |
| MIPI score | |||||
| Low | 47 (53) | 22 (47) | 16 (70) | 9 (50) | .13‡ |
| Intermediate | 16 (18) | 11 (23) | 5 (22) | 0 (0) | |
| High | 17 (19) | 6 (13) | 2 (9) | 9 (50) | |
| Missing | 8 (9) | 8 (17) | 0 (0) | 0 (0) | |
| LDH > ULN | |||||
| No | 54 (61) | 27 (57) | 18 (78) | 9 (50) | .16† |
| Yes | 27 (31) | 13 (28) | 5 (22) | 9 (50) | |
| Missing | 7 (8) | 7 (15) | 0 (0) | 0 (0) | |
| Ki67 | |||||
| ≤30% | 49 (56) | 27 (57) | 12 (52) | 10 (56) | >.99† |
| >30% | 21 (24) | 12 (26) | 5 (22) | 4 (22) | |
| Missing | 18 (20) | 8 (17) | 6 (26) | 4 (22) | |
| MCL subtype | |||||
| Other | 76 (86) | 40 (85) | 23 (100) | 13 (72) | .037† |
| Blastoid/pleomorphic | 11 (12) | 7 (15) | 0 (0) | 4 (22) | |
| Missing | 1 (1) | 0 (0) | 0 (0) | 1 (6) | |
| Treating center | |||||
| Community | 8 (9) | 8 (17) | 0 (0) | 0 (0) | .025† |
| Academic | 80 (91) | 39 (83) | 23 (100) | 18 (100) | |
| . | Total (N = 88) . | Patient cohort, n (%) . | P . | ||
|---|---|---|---|---|---|
| DFCI off-trial (n = 47 [53%]) . | DFCI trial (n = 23 [26%]) . | WUSTL trial (n = 18 [20%]) . | |||
| Age, y | |||||
| Median (range) | 58 (30-72) | 58 (30-72) | 57 (42-69) | 60 (38-65) | .97* |
| >60 | 36 (41) | 20 (43) | 8 (35) | 8 (44) | .84† |
| Male sex | 64 (73) | 32 (68) | 15 (65) | 17 (94) | .056† |
| Stage at diagnosis | |||||
| 1 | 1 (1) | 0 (0) | 0 (0) | 1 (6) | .80‡ |
| 2 | 1 (1) | 1 (2) | 0 (0) | 0 (0) | |
| 3 | 11 (12) | 7 (15) | 3 (13) | 1 (6) | |
| 4 | 75 (85) | 39 (83) | 20 (87) | 16 (89) | |
| ECOG PS | |||||
| 0-1 | 84 (95) | 47 (100) | 22 (96) | 15 (83) | .013† |
| 2 | 4 (5) | 0 (0) | 1 (4) | 3 (17) | |
| Days from diagnosis to treatment, median (range) | 32 (0-1539) | 31 (3-1388) | 40 (12-245) | 21 (0-1539) | .031* |
| MIPI score | |||||
| Low | 47 (53) | 22 (47) | 16 (70) | 9 (50) | .13‡ |
| Intermediate | 16 (18) | 11 (23) | 5 (22) | 0 (0) | |
| High | 17 (19) | 6 (13) | 2 (9) | 9 (50) | |
| Missing | 8 (9) | 8 (17) | 0 (0) | 0 (0) | |
| LDH > ULN | |||||
| No | 54 (61) | 27 (57) | 18 (78) | 9 (50) | .16† |
| Yes | 27 (31) | 13 (28) | 5 (22) | 9 (50) | |
| Missing | 7 (8) | 7 (15) | 0 (0) | 0 (0) | |
| Ki67 | |||||
| ≤30% | 49 (56) | 27 (57) | 12 (52) | 10 (56) | >.99† |
| >30% | 21 (24) | 12 (26) | 5 (22) | 4 (22) | |
| Missing | 18 (20) | 8 (17) | 6 (26) | 4 (22) | |
| MCL subtype | |||||
| Other | 76 (86) | 40 (85) | 23 (100) | 13 (72) | .037† |
| Blastoid/pleomorphic | 11 (12) | 7 (15) | 0 (0) | 4 (22) | |
| Missing | 1 (1) | 0 (0) | 0 (0) | 1 (6) | |
| Treating center | |||||
| Community | 8 (9) | 8 (17) | 0 (0) | 0 (0) | .025† |
| Academic | 80 (91) | 39 (83) | 23 (100) | 18 (100) | |